




Advancing Transfusion and Cellular Therapies Worldwide

AABB Survey: Impact of upcoming changes to CCP use


Highlights

- Survey conducted from Feb. 22-24, 2021.
- 224 hospitals responded.
- 38.7% hospitals plan to continue high-titer CCP use through May 31 and beyond.
- 37.1% are not yet clear on whether CCP use will change or not.
- Only 5.8% (n=13) hospitals are planning to discontinue CCP or have already done so. Among these hospitals, lack of stronger efficacy data followed by plan to shift towards other treatments were the two most common factors for discontinuation.
- 132 (~ 73%, total response=181) hospitals have discussed the availability of high titer CCP with their blood supplier.
- Most hospitals are willing to continue transfusing CCP if the reimbursement structure changes to a more traditional model.
- Most hospitals believe availability of high titer units will have the biggest impact on their CCP use in the future.
- A majority of the hospitals reported the use of CCP was at the entirely at the discretion of the ordering physician.


Anticipated impact of revised EUA and potential payment changes in the CCP use




Discussed the availability of high titer CCP with blood supplier




Continue to transfuse CCP if the reimbursement structure changes




Biggest impact on CCP use in the future



Patient selection and CCP use



Reasons to discontinue use of CCP*



* Response ratio presented based on a multi-select question. 13 hospitals responded as planning to discontinue CCP use or have already done so.